Current and emerging therapies for the treatment of myasthenia gravis.
about
Animal models of myasthenia gravis: utility and limitationsRisk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08Determinants of quality of life in Brazilian patients with myasthenia gravis.Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang.Clinical characteristics and therapeutic evaluation of childhood myasthenia gravis.Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravisClinical Profile and Outcome of Postthymectomy versus Non-Thymectomy Myasthenia Gravis Patients in the Philippine General Hospital: A 6-Year Retrospective Study.Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Clinical Study of Effects of Jian Ji Ning, a Chinese Herbal Medicine Compound Preparation, in Treating Patients with Myasthenia Gravis via the Regulation of Differential MicroRNAs Expression in Serum.Overcoming challenges in the diagnosis and treatment of myasthenia gravis.Optimization of current and future therapy for autoimmune diseases.Myasthenia gravis: the role of complement at the neuromuscular junction.Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment.When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.7th International Immunoglobulin Conference: Interlaken Leadership Awards.Myasthenic Crisis In Pregnancy.
P2860
Q26750632-F3DE7A3D-66F1-4FFC-BF3C-561821952614Q28943379-501A7C59-1997-4046-8D48-401E3FD32B2FQ30357085-0B64E3F6-476B-4FDB-AD09-5B9D19DF3FB5Q34354027-CB1D2B1A-8673-47B2-A7F6-D79095D6DB40Q35159667-3ABBAF33-15AB-4640-B229-D22A707ED389Q36412107-5AE9C955-22DF-4F7A-8245-20CDD692115CQ37022836-5F8A0B5D-1C33-48DE-B17D-17D07C43A5E0Q37967185-A1BA57F0-F7FD-4A2D-B2E2-C67F064C8DE8Q38295463-6BC1CE1B-4E20-4C4F-801F-5CE5189065FFQ38671442-1BB190D5-F920-4A5D-BDEE-A4F3A09ED893Q39666645-0E4C3380-8F07-44DA-B828-1299AEBFA247Q47266287-12335205-87C7-42E8-A4A3-BE2A5698E5D5Q47561172-087B42AA-47F9-4744-885B-D08FD57CEA89Q49280339-F0456D72-B800-4088-9A94-3FB4F6736999Q54299706-1B7C7D1B-7FFB-42EB-9D6A-A4310E00761EQ55101195-28347C65-298C-4749-B86E-050DD7696E62
P2860
Current and emerging therapies for the treatment of myasthenia gravis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Current and emerging therapies for the treatment of myasthenia gravis.
@ast
Current and emerging therapies for the treatment of myasthenia gravis.
@en
Current and emerging therapies for the treatment of myasthenia gravis.
@nl
type
label
Current and emerging therapies for the treatment of myasthenia gravis.
@ast
Current and emerging therapies for the treatment of myasthenia gravis.
@en
Current and emerging therapies for the treatment of myasthenia gravis.
@nl
prefLabel
Current and emerging therapies for the treatment of myasthenia gravis.
@ast
Current and emerging therapies for the treatment of myasthenia gravis.
@en
Current and emerging therapies for the treatment of myasthenia gravis.
@nl
P2860
P356
P1476
Current and emerging therapies for the treatment of myasthenia gravis.
@en
P2093
Giorgia Camera
Silvia Bonanno
P2860
P304
P356
10.2147/NDT.S8915
P407
P577
2011-03-22T00:00:00Z